Different Way

The point of personalized medicine, as the mantra goes, is to bring the right treatment to the right patient at the right time. But getting such tailored therapies approved may mean that how clinical trials assessing their efficacy and safety are conducted needs to be re-thought, writes Susan Young at Technology Review.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

The Pair of Them

This Week in Nature

This Week in PLOS

New Treatments to Try

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."